The Analysis of Risk Factors and Drug Resistance of CRE Infection in Children’s Intensive Care Unit
-
摘要:
目的 研究重症监护病区患儿CRE感染的耐药情况及发生CRE医院感染的危险因素,为儿童治疗CRE感染和医院制定感染防控策略提供参考依据。 方法 回顾性分析2019年1月至2022年12月入住云南省某三甲儿童医院重症监护病区患儿的临床资料,将92例耐碳青霉烯类肠杆菌科细菌(CRE)医院感染的患儿纳入病例组,按1∶1随机选择同期92例对碳青霉烯类敏感肠杆菌科细菌(CSE)感染的患儿纳入对照组,进行菌株鉴定和药敏试验,分析感染菌株和耐药情况,并通过SPSS 26.0对CRE感染患儿进行单因素和多因素Logistic回归分析,探究重症患儿发生CRE感染的相关危险因素。 结果 CRE感染菌株检出最多的为肺炎克雷伯菌81例(88.04%),其次为大肠埃希菌5例(5.43%)。CRE组左氧氟沙星、阿莫西林/克拉维酸、头孢他啶、亚胺培南、头孢吡肟、头孢曲松、阿米卡星耐药率均高于CSE组,均显示差异有统计学意义(P < 0.05)。单因素分析结果显示,留置胃管、中心静脉置管、机械通气、碳青霉烯类、抗真菌药、糖肽类及多粘菌素类抗生素使用史、抗生素药物使用种类≥3种、抗生素药物使用时间、碳青霉烯类抗生素使用时间、入住ICU时间和总住院时间均是CRE感染的危险因素,显示差异有统计学意义(P < 0.05)。多因素Logistic回归分析显示,碳青霉烯类抗生素使用史及使用时间和抗菌药物使用时间(P < 0.05)是重症患儿CRE感染的独立危险因素。 结论 结合重症患儿CRE感染的危险因素,尽量减少穿刺置管等侵入性操作,规范抗生素药物在重症患儿治疗中的使用管理,特别是碳青霉烯类抗生素,尽可能缩短患儿入住ICU时长和总住院时长,加强对重症患儿CRE的主动筛查,制定合理有效的感染防控策略,减少重症患儿CRE院内感染的发生。 Abstract:Objective To study the drug resistance of CRE infection in children in the intensive care unit and the risk factors of nosocomial infection of CRE, and to provide the reference for the treatment of CRE infection in children and the formulation of infection prevention and control strategies in hospitals. Methods Clinical data of children admitted to the intensive care unit of a 3A Children’s Hospital in Yunnan Province from January 2019 to December 2022 were retrospectively analyzed. 92 cases with nocometary infection of carbapenem-resistant enterobacteriaceae bacteria (CRE) were included in the case group, and 92 cases with carbapenem-sensitive enterobacteriaceae (CSE) infection were randomly selected at 1∶1. According to the group, strain identification and drug sensitivity test were carried out to analyze the infection strains and drug resistance. Univariate and multivariate logistic regression analysis was conducted for children with CRE infection by SPSS 26.0, to explore the risk factors related to CRE infection in severely ill children. Results Klebsiellapneumoniae was detected in 81 cases (88.04%), followed by Escherichiacoli in 5 cases (5.43%). The drug resistance rates of levofloxacin, amoxicillin/clavulanic acid, ceftazidime, imipenem, cefepime, ceftriaxoneand amikacin in CRE group were higher than those in CSE group, and the differences were statistically significant (P < 0.05).Univariate analysis showed that indwelling gastric tube, central venous catheterization, mechanical ventilation, history of using carbapenems, glycopeptides and polymyxin antibiotics, types of antibiotics used ≥3, time of using antibiotics, time of using carbapenems, time of staying in ICU and total hospital stay were all risk factors of CRE infection, showing statistically significant differences (P < 0.05).Multivariate logistic regression analysis showed that carbapenem antibiotic use history and use time and antibacterial use time (P < 0.05) were independent risk factors for CRE infection in severely ill children. Conclusion Combined with the risk factors of severe children’s CRE infection, we should minimize invasive operations such as puncture and intubation, standardize the use and management of antibiotics in the treatment of severe children, especially carbapenem antibiotics, shorten the length of stay in ICU and the total length of stay as much as possible, strengthen the active screening of severe children’s CRE, formulate reasonable and effective infection prevention and control strategies, and reduce the occurrence of nosocomial infection of severe children’s CRE. -
Key words:
- Children’s intensive care unit /
- CRE /
- Risk factors /
- Drug resistance
-
表 1 儿童重症监护病区CRE和CSE感染菌株分布(n = 92)
Table 1. Distribution of CRE and CSE infection in children’s intensive care unit (n = 92)
细菌 CRE组 CSE组 感染(n) 构成比(%) 感染(n) 构成比(%) 肺炎克雷伯菌 81 88.04 81 88.04 大肠埃希菌 5 5.43 5 5.43 阴沟肠杆菌 3 3.26 3 3.26 产酸克雷伯菌 3 3.26 3 3.26 表 2 CRE和CSE检出菌株对抗菌药物耐药率的比较
Table 2. Comparison of the drug resistance rates of the bacterial strains detected between the CRE and CSE
抗菌药物 CRE组(n = 92) CSE组(n = 92) χ2 P 耐药株数 耐药率(%) 耐药株数 耐药率(%) 左氧氟沙星 35 38.04 13 14.13 13.642 < 0.001* 复方新诺明 50 54.35 43 46.74 1.065 0.302 阿莫西林/克拉维酸 92 100 24 26.09 107.862 < 0.001* 头孢吡肟 92 100 30 32.61 93.508 < 0.001* 头孢曲松 92 100 55 59.78 46.313 < 0.001* 头孢他啶 92 100 36 39.13 80.500 < 0.001* 亚胺培南 90 97.83 0 0.00 176.170 < 0.001* 阿米卡星 25 27.17 0 0.00 28.931 < 0.001* *P < 0.05。 表 3 儿童重症监护病区CRE感染的单因素分析[n(%)/M(P25,P75))]
Table 3. Univariate analysis of CRE infection in children’s intensive care unit [n(%)/M(P25,P75)]
危险因素 CRE组 CSE组 χ2/Z P 性别 男 54(58.70) 51(55.43) 0.200 0.655 女 38(41.30) 41(44.57) 年龄 新生儿期 28(30.43) 21(22.83) 4.526 0.496 婴儿期 51(55.43) 62(67.39) 幼儿期 4(4.35) 5(5.43) 学龄前期 2(2.17) 1(1.09) 学龄期 6(6.52) 3(3.26) 青春期 1(1.09) 0(0.00) 民族 汉族 71(77.17) 67(72.83) 0.464 0.496 少数民族 21(22.83) 25(27.17) 既往住院史 62(67.39) 49(53.26) 3.838 0.050 外科手术史 15(16.30) 8(8.70) 2.435 0.119 侵入性操作 留置胃管 81(88.04) 64(69.57) 9.403 0.002* 中心静脉置管 75(81.52) 56(60.87) 9.567 0.002* 留置尿管 33(35.87) 29(31.52) 0.389 0.533 机械通气 70(76.09) 53(57.61) 7.087 0.008* 气管插管/切开 57(61.96) 44(47.83) 3.709 0.054 抗生素药物使用史 碳青霉烯类 67(72.83) 35(38.04) 22.527 < 0.001* β-内酰胺类抗菌药物的
复合剂65(70.65) 60(65.22) 0.624 0.430 一或二代头孢菌素类 12(13.04) 21(22.83) 2.991 0.084 三或四代头孢菌素类 57(61.96) 50(54.35) 1.094 0.296 糖肽类 31(33.70) 16(17.39) 6.430 0.011* 抗真菌药 38(41.30) 24(26.09) 4.768 0.029* 氨基糖苷类 3(3.26) 1(1.09) 1.022 0.312 大环内酯类 20(21.74) 17(18.48) 0.304 0.581 青霉素类 27(29.35) 23(25.00) 0.439 0.507 头霉素类 2(2.17) 0(0.00) 0.505 0.477 甘氨酰环素类 1(1.09) 2(2.17) 0.339 0.560 喹诺酮类 2(2.17) 0(0.00) 0.505 0.477 磺胺类 2(2.17) 0(0.00) 0.505 0.477 多粘菌素类 9(9.78) 0(0.00) 7.477 0.006* 恶唑烷酮类 3(3.26) 1(1.09) 1.022 0.312 氧头孢烯类 7(7.61) 5(5.43) 0.357 0.550 四环素类 4(4.35) 0(0.00) 2.300 0.129 抗生素药物使用种类 < 3种 25(27.17) 45(48.91) 9.223 0.002* ≥3种 67(72.83) 47(51.09) 抗生素药物使用时间(d) 30.00(14.25,42.75) 15.00(9.00,27.75) −4.103 < 0.001* 碳青霉烯类抗生素
使用时间(d)14.50(0.00,24.00) 0.00(0.00,11.00) −5.158 < 0.001* 入住ICU时间(d) 20.50(9.25,39.00) 13.00(7.00,23.25) −3.056 0.002* 总住院时间(d) 33.50(18.25,48.75) 19.50(13.00,32.75) −3.691 < 0.001* *P < 0.05。 表 4 儿童重症监护病区CRE感染的多因素Logistic回归分析
Table 4. Multivariate logistic regression analysis of CRE infection in children’s intensive care unit
危险因素 β SE Wald P OR及其95%CI 常量 −1.070 0.372 8.252 0.004* 0.343 碳青霉烯类抗生素使用时间 0.085 0.026 11.024 0.001* 1.089(1.035,1.145) 碳青霉烯类使用史 1.352 0.487 7.702 0.006* 3.864(1.487,10.036) 抗生素药物使用时间 0.051 0.023 4.789 0.029* 1.052(1.005,1.102) *P < 0.05。 -
[1] 张琴,许健,宋培培. 儿童患者检出耐碳青霉烯类抗菌药物肠杆菌科细菌分布特征及耐药性分析[J]. 中国抗生素杂志,2020,45(12):1273-1278. doi: 10.3969/j.issn.1001-8689.2020.12.012 [2] Willyard C. The drug-resistant bacteria that pose the greatest health threats[J]. Nature,2017,543(7643):15. doi: 10.1038/nature.2017.21550 [3] 周冉,方玉婷,苏丹,等. 儿童耐碳青霉烯类肠杆菌目细菌感染治疗药物研究进展[J]. 中国感染控制杂志,2022,21(2):204-208. [4] Logan L K. Carbapenem-resistant enterobacteriaceae: An emerging problem in children[J]. Clin Infect Dis,2012,55(6):852-859. doi: 10.1093/cid/cis543 [5] 员静,单斌,孟雪斐,等. 2018—2020年多中心耐碳青霉烯类肠杆菌目细菌的流行病学特征及耐药性分析[J]. 中国抗生素杂志,2021,46(11):1038-1043. doi: 10.3969/j.issn.1001-8689.2021.11.009 [6] 中华人民共和国卫生部. 医院感染诊断标准(试行)[J]. 中华医学杂志,2001,81(5):314-320. doi: 10.3760/j:issn:0376-2491.2001.05.027 [7] Bartsch S M,McKinnell J A,Mueller L E,et al. Potential economic burden of carbapenem-resistant enterobacteriaceae(CRE) in the United States[J]. Clin Microbiol Infect,2017,23(1):48.e9-48.e16. doi: 10.1016/j.cmi.2016.09.003 [8] 于佳,张静,李莉珊,等. ICU患者耐碳青霉烯类肠杆菌科细菌感染特征及危险因素[J]. 中华医院感染学杂志,2022,32(21):3215-3219. [9] 刘思娣,吴安华,李春辉,等. 高危科室住院患者肠道耐碳青霉烯类肠杆菌科细菌筛查及其阳性危险因素[J]. 中华医院感染学杂志,2023,33(4):517-521. [10] 房锐颖,张亚萍,陶云珍,等. 苏州大学附属儿童医院碳青霉烯类耐药肠杆菌目细菌流行特征及耐药基因分析[J]. 安徽医学,2022,43(3):271-275. doi: 10.3969/j.issn.1000-0399.2022.03.005 [11] 付盼,王传清,俞蕙,等. 中国儿童细菌耐药监测组2018年儿童细菌感染及耐药监测[J]. 中国循证儿科杂志,2019,14(5):321-326. [12] 张甜甜,刘志武,徐腾飞,等. 某三甲医院耐碳青霉烯类肠杆菌科细菌耐药性和耐消毒剂基因分析[J]. 中华医院感染学杂志,2023,33(3):325-329. [13] 中国碳青霉烯耐药肠杆菌科细菌感染诊治与防控专家共识编写组,中国医药教育协会感染疾病专业委员会,中华医学会细菌感染与耐药防控专业委员会. 中国碳青霉烯耐药肠杆菌科细菌感染诊治与防控专家共识[J]. 中华医学杂志,2021,101(36):2850-2860. [14] 黄兰清,陈清秀,蔡榕,等. 儿童重症监护病区多重耐药菌感染情况及危险因素[J]. 中华医院感染学杂志,2020,30(9):1436-1440. [15] 林碧玉,刘婧婷,金凤玲. 儿童耐碳青霉烯类肠杆菌定植或感染危险因素的Meta分析[J]. 中国当代儿科杂志,2022,24(1):96-101. doi: 10.7499/j.issn.1008-8830.2109025 [16] 许渝,黄砚屏,罗万军. 新生儿耐碳青霉烯类肠杆菌感染影响因素[J]. 中国感染控制杂志,2020,19(12):1098-1101. doi: 10.12138/j.issn.1671-9638.20206029 [17] Al-Gethamy M M,Faidah H S,Adetunji H A,et al. Risk factors associated with multi-drug-resistant Acinetobacter baumannii nosocomial infections at a tertiary care hospital in Makkah,Saudi Arabia - a matched case-control study[J]. J Int Med Res,2017,45(3):1181-1189. doi: 10.1177/0300060517706284 [18] Li X,Xu X,Yang X,et al. Risk factors for infection and/or colonisation with extended-spectrum β-lactamase-producing bacteria in the neonatal intensive care unit: A meta-analysis[J]. Int J Antimicrob Agents,2017,50(5):622-628. doi: 10.1016/j.ijantimicag.2017.06.027 [19] Chiotos K,Tamma P D,Flett K B,et al. Multicenter study of the risk factors for colonization or infection with carbapenem-resistant enterobacteriaceae in children[J]. Antimicrob Agents Chemother,2017,61(12):e01440. [20] 杨欣,鲁利群,黄莉,等. 儿科碳青霉烯类耐药肺炎克雷伯菌感染危险因素及其耐药性[J]. 中华医院感染学杂志,2020,30(22):3470-3473.